Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.

ABSTRACT:

Background

To identify baseline patient characteristics associated with early clinically significant visual acuity (VA) improvements within 3 months of treatment initiation in ranibizumab-treated patients with retinal vein occlusion (RVO) in the SHORE study.

Methods

Post hoc analysis of baseline patient characteristics in the randomized, open-label, vision examiner-masked SHORE phase 4 study that compared monthly versus pro re nata dosing of ranibizumab in patients with branch and central RVO. Patients who enrolled in SHORE fulfilled eligibility criteria per protocol (N = 202). SHORE data were retrospectively analyzed to identify baseline patient characteristics associated with early clinically significant improvements in VA, defined as improvement to a Snellen equivalent of

SUBMITTER: Lloyd Clark W 

PROVIDER: S-EPMC6325686 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature